AUTHOR=Pang Wenyang , Cheng Shulin , Du Zhongbo , Du Shuang 

TITLE=The diagnostic performance of 18F-DCFPyL PET in patients with suspected prostate cancer: A systemic review and meta-analysis

JOURNAL=Frontiers in Oncology

VOLUME=Volume 13 - 2023

YEAR=2023

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1145759

DOI=10.3389/fonc.2023.1145759

ISSN=2234-943X

ABSTRACT=Introduction Our meta-analysis aimed to evaluate the diagnostic value of 18F-DCFPyL PSMA PET in patients with suspected prostate cancer. 
Methods We searched for articles that evaluate the diagnostic value of 18F-DCFPyL PSMA PET in patients with suspected prostate cancer in PubMed, Embase, Cochrane Library, and Web of Science until August 1, 2022. Using the QUADAS-2 instrument, two researchers independently assessed the effectiveness of the studies that were included. The four-grid table data were analyzed by Meta-disc1.4 and Stata 16.0 software. The heterogeneity of each study was tested.
Results A total of 5 studies with 258 patients were included, and the pooled sensitivity and specificity of 18F-DCFPyL PSMA PET for primary prostate cancer were shown as follows: 0.92 (95% Confidence interval (CI): 0.85-0.96), 0.59 (95% CI: 0.08-0.96), respectively. 18F-DCFPyL PSMA PET was successful in detecting primary prostate cancer, with an AUC of 0.92 (95% CI: 0.89-0.94).
Conclusions 18F-DCFPYL PSMA PET has a strong predictive value for primary prostate cancer and is an effective method for the noninvasive diagnosis of prostate cancer. More prospective articles were needed.